New asthma drug tezepelumab tested in everyday clinics

NCT ID NCT06724575

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 155 adults with severe asthma who are starting tezepelumab, a new biologic drug. Researchers will track symptom control, quality of life, and lung function over two years in real-life clinics across Greece. The goal is to see how well the drug works outside of strict trial conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tezepelumab
What this could lead to: If successful, this study could show that tezepelumab helps control severe asthma symptoms and improves quality of life in real-world settings, supporting its wider use.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It only includes patients in Greece, which may limit how well findings apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Research Site

Alexandroupoli, Greece
Research Site

Athens, Greece
Research Site

Corfu, Greece
Research Site

Crete, Greece
Research Site

Ioannina, Greece
Research Site

Larissa, Greece
Research Site

Pátrai, Greece
Research Site

Thessaloniki, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.